22.418 articles found

Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, Prats A, Pons F, Bernardo M.

Psychopharmacology (Berl) · 2006-09-22

DOI: 10.1007/s00213-006-0570-5PMID: 17019564

THERAPEUTIC CELL MEDICINE COMPRISING SKIN TISSUE DERIVED STEM CELL

KANG SOO KYUNG.

· 2006-09-21

Partial mGluR5 antagonists for treatment of anxiety and CNS disorders

CONN P. J, RODRIGUEZ ALICE L, JONES CARRIE K, CONN P. JEFFREY.

· 2006-09-20

TREATMENT OF SYMPTOMS OF PARKINSON'S DISEASE

NISSINEN HELENA, VAHTERISTO MIKKO, KUOPPAMAEKI MIKKO, ELLMEN JUHA, LEINONEN MIKA.

· 2006-09-20

Partial mGluR5 antagonists for treatment of anxiety and CNS disorders

CONN P. J, RODRIGUEZ ALICE L, JONES CARRIE K, CONN P. JEFFREY.

· 2006-09-20

An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia.

Rocha FL, Hara C, Ramos MG, Kascher GG, Santos MA, de Oliveira Lança G, Magalhães Scoralick F.

Dement Geriatr Cogn Disord · 2006-09-15

DOI: 10.1159/000095804PMID: 16983187

Role of autophagy in the clearance of mutant huntingtin: a step towards therapy?

Ravikumar B, Rubinsztein DC.

Mol Aspects Med · 2006-09-14

DOI: 10.1016/j.mam.2006.08.008PMID: 16973207

THERAPEUTIC AGENT FOR PARKINSON'S DISEASE OR PARKINSONIAN SYNDROME CONTAINING CELL RELATING TO MESENCHYMAL SYSTEM AND THERAPEUTIC METHOD USING THE SAME

HONMO OSAMU, TSUJI NORIKO, HOKIN KIYOHIRO.

· 2006-09-08

The therapeutic potential of the calpain family: new aspects.

Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A.

Drug Discov Today · 2006-09-07

DOI: 10.1016/j.drudis.2006.08.009PMID: 16997142

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.

Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ.

Schizophr Res · 2006-09-07

DOI: 10.1016/j.schres.2006.07.010PMID: 16959472

In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.

Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.

J Pharmacol Exp Ther · 2006-09-07

DOI: 10.1124/jpet.106.110429PMID: 16959959

Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.

Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ.

J Neurol Neurosurg Psychiatry · 2006-09-04

DOI: 10.1136/jnnp.2006.098079PMID: 16952917